The Role of Plasmapheresis in Acute Rejection with Decompensated Heart Failure after Heart Transplantation
Öz
Abstract
Background/Aims: In this study, the results of patients who had orthotopic heart transplantation (OHT) in acute rejection who admitted to our clinic with decompensated heart failure and who could not undergo endomyocardial biopsy (EMB) were evaluated.
Methods: The study included 27 patients who underwent OHT in our clinic between December 1998 and November 2021, who admitted with acute rejection causing decompensated heart failure during follow-up, and who could not undergo EMB and administered IV pulse steroid plus plasmapheresis. Demographics of patients, peri-treatment left ventricular functions, survival rates and causes of mortality were analyzed.
Results: 19 (70.4%) were male and mean age was 28.7 ± 14.7 (range: 3-54). After OHT, overall survival rates were 92.6%, 77.6%, and 69.4% at 1st, 3rd and 5th year respectively. During the follow-up, the survival rates of patients who presented with decompensated heart failure and given pulse steroid plus plasmapheresis were 70.4%, 58.8%, and 53.4% at 1st, 3rd and 5th year respectively after plasmapheresis. Median rejection time after transplant was 19 months (range 0-113 months). Pre-, and post-treatment left ventricle ejection fractions were 25.11% ± 11.1%, and 52.14% ± 13.4% respectively (p<0.05). The leading causes of mortality were pneumonia causing sepsis (5/13 patients).
Conclusions: In acute rejection patients with decompensated heart failure in whom EMB is not possible, administration of plasmapheresis in addition to IV pulse steroid therapy may have a positive effect on survival in this patient group.
Anahtar Kelimeler
Kaynakça
- Khush KK, Hsich E, Potena L, Cherikh WS, Chambers DC, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult heart transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant 2021;40(10):1035-49.
- Rodriguez ER, Tan CD. The Pathology of Heart Transplantation. In: Ruiz P, editor. Transplantation Pathology 2 ed Cambridge: Cambridge University Press 2018. p. 133-55.
- Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation 2015;131(18):1608-39.
- Chou HW, Chi NH, Lin MH, Chou NK, Tsao CI, Yu HY, et al. Steroid pulse therapy combined with plasmapheresis for clinically compromised patients after heart transplantation. Transplant Proc 2012;44(4):900-2.
- Pajaro OE, Jaroszewski DE, Scott RL, Kalya AV, Tazelaar HD, Arabia FA. Antibody-mediated rejection in heart transplantation: case presentation with a review of current international guidelines. J Transplant 2011;2011:351950.
- Kervan U, Sert DE, Turan N. Humoral Rejection in Cardiac Transplantation: Management of Antibody-Mediated Rejection: IntechOpen 2018.
- Herskowitz A, Soule LM, Ueda K, Tamura F, Baumgartner WA, Borkon AM, et al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients. J Heart Transplant 1987;6(3):127-36.
- Hammond EH, Yowell RL, Nunoda S, Menlove RL, Renlund DG, Bristow MR, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989;8(6):430-43.
- Michaels PJ, Espejo ML, Kobashigawa J, Alejos JC, Burch C, Takemoto S, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22(1):58-69.
- Uber WE, Self SE, Van Bakel AB, Pereira NL. Acute antibody-mediated rejection following heart transplantation. Am J Transplant 2007;7(9):2064-74.